Persistence of Antibodies Six Months after Three COVID-19 mRNA Vaccine Doses in Patients with Inflammatory Bowel Disease

Caldera, Freddy; Richard, Luke; Almasry, Mazen; Phan, Hiep; Chun, Kelly; Farraye, Francis A.; Hayney, Mary S.

doi:10.1093/ibd/izad019

Cited by 4 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Humoral Immune Responsementioning

confidence: 99%

“…Additionally, despite a lower mean antibody level, greater than 98% of patients with IBD still demonstrate a sustained humoral immune response 6 months after a third dose (with higher antibody levels in those with previous COVID-19 infection). 41 Lastly, it should be noted that several studies have shown lower rates of seroconversion in those who received a viral vector vaccine. 35,40,42 This included data from the PREVENT-COVID cohort, in which the rate of seroconversion in 94 patients who received Ad26.COV2.S was 81% at 3 months and antibody concentrations were significantly lower than in those who received an mRNA vaccine (median 2.7 μg/mL versus 17 μg/ mL with mRNA vaccines).…”

Section: Humoral Immune Responsementioning

confidence: 99%

See 1 more Smart Citation

COVID-19 vaccination in adults with inflammatory bowel disease

Lutz

Lazarus

Caldera

2023

Therap Adv Gastroenterol

Self Cite

View full text Add to dashboard Cite

Patients with inflammatory bowel disease (IBD) are not at increased risk of SARS-CoV-2 infection compared to the general population, and most are not at increased risk for severe disease. COVID-19 is nonetheless common, and vaccination is critical. Four safe and efficacious vaccines are now available for the prevention of COVID-19, with most data available for mRNA vaccines. Patients with IBD have a robust humoral response to vaccination with rates of seroconversion exceeding 95% following a two-dose mRNA vaccine series and 99% following a three-dose mRNA series, although those on certain therapies including anti-tumor necrosis factor α agents may have lower antibody concentrations and waning of antibodies over time. Additionally, rates of cell-mediated immune response, even in those patients with IBD who did not have evidence of humoral immunity, are high. Vaccines are safe and have not been associated with flares in disease activity. Gastroenterology providers should take an active role in ensuring patients with IBD are appropriately vaccinated against COVID-19.

show abstract

Section: Humoral Immune Responsementioning

confidence: 99%